JupiteX Get the app
Health & Medicine19 Nov 2026 · about 7 min

What a Wearable ‘Wellness’ Device Tells Us About Regulatory Gaps in India and Abroad

The brief

Temple 01 is a screen-less optical sensor that weighs less than two grams and is less than an inch wide. It attaches to the side of the head, between the ear and tape, using medical-grade tape. Its small size makes it a wearable, but the claims reach beyond ordinary activity tracking. Temple says the device tracks heart rate and a proprietary “Brain Flow” index intended to reflect changes in cerebral circulation. It also gives the wearer an Entropy score. The company presents the device as a way to see how sleep, exercise, posture and caffeine affect the brain over days and weeks. The article gives evidence details for heart rate and Brain Flow, but not a definition or validation study for Entropy. Temple has described itself as a fitness tracker and wellness device, not a medical device. Its proposed voice AI companion is a future addition, not part of the sensor’s stated measurements.

01

What is Temple 01, and what does it claim to measure?

Temple 01 is a screen-less optical sensor that weighs less than two grams and is less than an inch wide. It attaches to the side of the head, between the ear and tape, using medical-grade tape. Its small size makes it a wearable, but the claims reach beyond ordinary activity tracking.

Temple says the device tracks heart rate and a proprietary “Brain Flow” index intended to reflect changes in cerebral circulation. It also gives the wearer an Entropy score. The company presents the device as a way to see how sleep, exercise, posture and caffeine affect the brain over days and weeks.

The article gives evidence details for heart rate and Brain Flow, but not a definition or validation study for Entropy. Temple has described itself as a fitness tracker and wellness device, not a medical device. Its proposed voice AI companion is a future addition, not part of the sensor’s stated measurements.

02

What evidence has Temple offered for its heart-rate, Brain Flow and Entropy claims, and what remains unverified?

Temple’s heart-rate evidence comes from a study it funded, ran and analysed. It compared readings from 43 healthy adults exercising on treadmills with a Polar H10 chest strap. Temple reported an average difference of 1.18 beats per minute, the smallest gap among six wearables tested.

For Brain Flow, a company preprint compared its index with transcranial Doppler readings in 23 young, healthy adults. It reported a correlation of about 0.79 under the test conditions. The article describes the signal as relative and normalised, and says Goyal’s Gravity Ageing Hypothesis is not proven. The supplied text gives no validation evidence or explanation for the Entropy score.

Neither claim has been independently replicated or peer-reviewed in the account provided. The heart study covered treadmill exercise, not daily life or other populations. Temple has offered devices to qualified researchers for independent testing, but that work remains a next step, not confirmation.

03

How many people and testing conditions have Temple’s published studies covered, and what situations were left out?

The article describes two separate sets of evidence: a heart-rate study involving 43 healthy adults aged 20 to 35, and a Brain Flow preprint involving 23 young, healthy adults. It does not establish whether the groups overlapped, so those figures should not be treated as a count of unique participants.

For heart rate, all six devices were worn during treadmill running, and their readings were compared with a Polar H10 chest strap. For Brain Flow, the comparison was with transcranial Doppler readings of blood velocity in the middle cerebral artery, under the preprint’s test conditions.

The heart-rate test did not cover sleep, daily life, other sports, older people or people who were not perfectly healthy. The article gives no broader conditions or populations for the Brain Flow test. Neither study, as described, shows how well the device performs across ordinary users and settings.

04

Why do independent replication and peer review matter when a company tests its own health-related device?

When a company tests its own device, it may know the product and its methods best, but its results have not yet faced an outside check. That does not make the findings false. It does mean readers have less reason to assume the results will hold in other settings or for other people.

Temple’s heart-rate study was funded, run and analysed by the company. Independent researchers could test the same device with their own methods and participants, then see whether they obtain similar results. Peer review gives other specialists a chance to scrutinise how a study was designed, analysed and reported before it is treated as strong evidence.

Neither process guarantees a device works, and one study cannot establish every use case. But the article says independent studies that would settle whether Temple works have not been undertaken. Temple has offered to loan devices to qualified researchers; replication and review would help clarify what the reported measurements can support.

05

How does classifying a wearable as a wellness product rather than a medical device affect the evidence and oversight it may face?

The label matters because health products can face different evidence and oversight expectations depending on what they claim to do. A product presented as helping with general wellbeing may be treated differently from one intended to diagnose or treat a medical condition. The exact rules depend on the jurisdiction and the product’s claims and intended use.

On November 5, Goyal called Temple a fitness tracker and wellness device, “not a medical device.” Yet the company’s central promise is that a sensor can show how well the brain is supplied with blood in real time. That sits close to a health-related claim, even as the product is sold as wellness technology.

The article does not specify Temple’s regulatory status or the detailed rules it faces. It describes a gap in which sellers draw boundaries, those boundaries are disputed online, and the state leaves them alone. Calling a product wellness does not, by itself, prove its measurements work or settle the appropriate oversight.

06

How do India and other jurisdictions draw the line between wellness products and medical devices, and where can gaps arise?

The supplied article describes a boundary problem but does not explain the detailed laws of India or other jurisdictions. As general regulatory context, rules commonly distinguish general wellness products from devices intended for medical purposes. The boundary can depend on a product’s intended use, claims and functions, and the details differ across countries.

In India, the CDSCO administers the Medical Devices Rules, 2017. In the United States, the FDA has a policy for certain low-risk general wellness products. In the European Union, the Medical Device Regulation generally turns on whether a product has a medical purpose. These are broad descriptions, not a determination of Temple’s status.

Gaps can arise when a product makes health-related claims but is marketed as wellness, or when responsibilities and evidence expectations are unclear. The article’s account of Temple captures that tension: the seller draws a line, people challenge it, and the state may not resolve the dispute. The provided text does not compare enforcement or outcomes across these jurisdictions.

07

What could happen if people use an unvalidated wellness score to make decisions about their health?

Temple says its measurements could help people see how sleep, exercise, posture and caffeine affect the brain. That makes the meaning of its scores important: users might treat a number as guidance for choices about their routine or health, even though the article says the key claims have not been independently settled.

If an unvalidated score were wrong or misunderstood, a person could become unnecessarily worried, feel falsely reassured, or make a change based on a signal that does not mean what they think it means. These are possible consequences of relying on uncertain health information, not outcomes reported in the article.

The article says Temple is positioned between wellness and medicine and that a 14-day returns policy cannot settle whether it works. Independent studies could clarify what the measurements show and what they do not. Until then, the evidence described is limited, especially for Brain Flow and Entropy, and the article does not establish that these scores can guide medical decisions.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web